A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,
None
None
Parallel
Aprepitant Injection
DrugBefore anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
Aprepitant Injection Placebo
DrugBefore anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds
Complete response (CR) rates over 24 hours after the end of surgery
Complete response (defined as no emetic episodes and no use of rescue therapy)
Proportion of participants who have no nausea in the 0 to 24 hours following the end of surgery
No nausea（defined as a visual analogue scale (VAS) nausea score \< 1.）
Proportion of participants who have significant nausea in the 0 to 24 hours following the end of surgery
Significant nausea（defined as a visual analogue scale (VAS) nausea score≥4）
Proportion of participants who have no vomiting or retching in the 0 to 24 hours following the end of surgery
No vomiting or retching（Defined as whether or not use remedy treatment had no vomiting）
Proportion of participants who use the remedial treatment in the 0 to 24 hours following the end of surgery
Number of participants with treatment-related adverse events as assessed by NIH
Safety was assessed by Adverse events (AEs) were recorded after administration.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
